Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-MESO CAR-T cells (Shanghai 6th People's Hospital)
- Development stage
- Unknown
- Lead developer
- Shanghai Sixth People’s Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-MESO CAR-T cells (Shanghai 6th People's Hospital) is an investigational fourth-generation chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin (MSLN). Developed by Shanghai 6th People's Hospital, this autologous cell therapy is designed for the treatment of refractory or relapsed ovarian cancer. The therapy utilizes patient-derived T cells genetically engineered to express a CAR that recognizes mesothelin, a glycoprotein highly expressed on the surface of ovarian cancer cells. As a fourth-generation CAR-T, it is designed to enhance anti-tumor activity, potentially through the localized secretion of anti-PD-1 antibodies to mitigate immune suppression within the tumor microenvironment. It is currently being evaluated in an Early Phase 1 clinical study to assess its safety, feasibility, and preliminary therapeutic potential in patients who have failed multiple prior lines of therapy.
- Other names
- Fourth Generation anti-mesothelin CAR-T cellsanti-Mesothelin Chimeric Antigen Receptor T-Cell
02
Targets
MesothelinPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on anti-MESO CAR-T cells (Shanghai 6th People's Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-MESO CAR-T cells (Shanghai 6th People's Hospital).